Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 6Phase 3 3Phase 1/2 3Phase NA 2Phase 4 2Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1

Conditions

Breast Neoplasms 134Neoplasms 112Polycystic Ovary Syndrome 66Prostatic Neoplasms 63Colorectal Neoplasms 51Carcinoma, Non-Small-Cell Lung 47Pain 40Carcinoma, Hepatocellular 35Lung Neoplasms 34Keratosis, Actinic 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Pain, Postoperative 26Neoplasm Metastasis 26Head and Neck Neoplasms 26Stomach Neoplasms 24Colonic Neoplasms 23Multiple Myeloma 22Brain Neoplasms 21Pancreatic Neoplasms 20Lymphoma, Follicular 19Leukemia 19Anemia 19Uterine Cervical Neoplasms 18Leukemia, Myeloid, Acute 18Infertility 18Leiomyoma 17Lymphoma, Non-Hodgkin 16Lymphoma 16Cancer Pain 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15

Interventions

arginyllysine 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × Carcinoid Tumor × Clear all
NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Advanced Accelerator Applications

Phase 4 Completed
42 enrolled 11 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡